OPKO makes strategic investment in biotech firm
US pharma and diagnostics firm OPKO Health (NYSE: OPK) has agreed to make an undisclosed strategic investment in privately-held biotech company Zebra Biologics, which is based on technology developed by Richard Lerner of the Scripps Research Institute.
Founding in July 2013 by leading scientists in antibody engineering, experienced biotech executives and private investors, Zebra aims to take advantage of new technologies developed by Dr Lerner and colleagues at The Scripps Research Institute in San Diego, to generate both agonist and antagonist antibody for a wide array of therapeutic applications. Zebra has obtained an exclusive license to these technologies and plans to enter into major R&D collaborative with pharmaceutical and biotechnology companies to bring a portfolio of “bio-superiors” antibodies into clinical development within the next two to five years.
Technology underlines Humira success
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze